Bio-pharmaceutical company Insmed Inc. (INSM) Tuesday announced additional results of the mid-stage trial of its lead drug candidate Arikayce, being developed for the treatment of Non-Tuberculous Mycobacteriae (NTM) lung infections.
The company said at the end of the 84-day trial, 78 of the 80 patients agreed to receive once-daily Arikayce plus standard of care for an additional 84 days. The results from the open label phase show that 21 of these patients were culture negative for NTM at Day 168.
"We are encouraged by these additional and durable culture conversions which we believe is the ultimate goal in the treatment of NTM lung infections," said Will Lewis, President and Chief Executive Officer of Insmed.
The phase 2 trial compared Arikayce added to standard of care treatment, versus standard of care treatment plus placebo, in 89 adult patients with treatment resistant NTM lung disease.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.